Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927938 · ClinicalTrials.gov registry record · Phase 3
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT02927938 is a Phase 3 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 18 participants.
The verdict
NCT02927938, a Phase 3 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) following induction chemotherapy. However, a large majority subsequently relapse and succumb to the disease. Currently, cytogenetics and molecular aberrations are the best prognostic indicators; however, these factors cannot prognosticate accurately for individual patients. Overall, the majority of patients with favorable or intermediate-risk AML will experience relapse. Prognosis after relapse is dismal with a five-year overall survival rate of less than 10%. A leukemia stem cell (LSC) paradigm may explain this failure of CR to reliably translate into cure. This study is undertaken to determine whether the presence of LSCs has prognostic value as well as to determine whether the presence of LSCs has predictive value. This study has an observational component, whereby we intent evaluate whether the presence or absence of LSCs is prognostic. This study also has an interventional component in which it uses LSC status to determine whether favorable and intermediate risk AML patients in CR receive consolidation with chemotherapy or allogeneic HCT.
Interventions
- PROCEDURE Allogeneic HCT
- DRUG Consolidation chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02927938
The ClinicalTrials.gov registry entry for NCT02927938 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allogeneic HCT is the first listed.
NCT02927938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02927938 about?
NCT02927938 is a clinical study titled "Leukemia Stem Cell Detection in Acute Myeloid Leukemia". Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) following induction chemotherapy. However, a large majority subsequently relapse and succumb to the disease. Currently, cytogenetics and molecular aberrations are the best prognostic indicators; however, these factors ca...
What is the current status of trial NCT02927938?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2016-09. Estimated completion is 2018-10-05.
What interventions are being tested in trial NCT02927938?
The interventions under investigation include: Allogeneic HCT (PROCEDURE), Consolidation chemotherapy (DRUG).
Who is sponsoring clinical trial NCT02927938?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.